Frontiers in Endocrinology (Jan 2023)

Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01)

  • Cesare C. Berra,
  • Maria Chiara Rossi,
  • Marco Mirani,
  • Daniela Ceccarelli Ceccarelli,
  • Cristina Romano,
  • Lorenza Sassi,
  • Elena Peretti,
  • Giuseppe Favacchio,
  • Ida Pastore,
  • Laura Folini,
  • Giusi Graziano,
  • Maria Elena Lunati,
  • Sebastiano Bruno Solerte,
  • Paolo Fiorina,
  • Paolo Fiorina

DOI
https://doi.org/10.3389/fendo.2022.1099451
Journal volume & issue
Vol. 13

Abstract

Read online

IntroductionAim of the present study was to evaluate the real-world impact of once-weekly (OW) subcutaneous semaglutide on different end-points indicative of metabolic control, cardiovascular risk factors, and beta-cell function in type 2 diabetes (T2D).MethodsThis was a retrospective, observational study conducted in 5 diabetes clinics in Italy. Changes in HbA1c, fasting blood glucose (FBG), body weight, blood pressure, lipid profile, renal function, and beta-cell function (HOMA-B) during 12 months were evaluated.ResultsOverall, 594 patients (97% GLP-1RA naïve) were identified (mean age 63.9 ± 9.5 years, 58.7% men, diabetes duration 11.4 ± 8.0 years). After 6 months of treatment with OW semaglutide, HbA1c levels were reduced by 0.90%, FBG by 26 mg/dl, and body weight by 3.43 kg. Systolic blood pressure, total and LDL-cholesterol significantly improved. Benefits were sustained at 12 months. Renal safety was documented. HOMA-B increased from 40.2% to 57.8% after 6 months (p<0.0001).DiscussionThe study highlighted benefits of semaglutide on metabolic control, multiple CV risk factors, and renal safety in the real-world. Semaglutide seems to be an advisable option for preservation of β-cell function and early evidence suggests it might have a role in modifying insulin resistance (HOMA-IR), the pathogenetic basis of prediabetes and T2D.

Keywords